Zacks Investment Research downgraded shares of Allena Pharmaceuticals (NASDAQ:ALNA) from a hold rating to a sell rating in a research report sent to investors on Monday.
According to Zacks, “Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. “
ALNA has been the subject of several other research reports. Jefferies Financial Group began coverage on shares of Allena Pharmaceuticals in a report on Thursday, November 8th. They set a buy rating and a $22.00 target price for the company. B. Riley reaffirmed a buy rating and issued a $22.00 price objective on shares of Allena Pharmaceuticals in a report on Friday, December 21st. ValuEngine raised shares of Allena Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday, December 12th. Finally, Wedbush reaffirmed a buy rating and issued a $38.00 price objective on shares of Allena Pharmaceuticals in a report on Tuesday, October 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $28.71.
Shares of Allena Pharmaceuticals stock opened at $7.95 on Monday. The company has a debt-to-equity ratio of 0.17, a current ratio of 14.75 and a quick ratio of 14.75. Allena Pharmaceuticals has a 1 year low of $4.80 and a 1 year high of $17.56. The firm has a market cap of $174.81 million, a P/E ratio of -1.66 and a beta of 1.31.
Allena Pharmaceuticals (NASDAQ:ALNA) last issued its earnings results on Wednesday, November 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.01. As a group, equities analysts anticipate that Allena Pharmaceuticals will post -1.77 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc increased its holdings in Allena Pharmaceuticals by 2.2% in the third quarter. Vanguard Group Inc now owns 349,819 shares of the company’s stock valued at $3,757,000 after buying an additional 7,400 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Allena Pharmaceuticals by 2.2% in the third quarter. Vanguard Group Inc. now owns 349,819 shares of the company’s stock valued at $3,757,000 after purchasing an additional 7,400 shares during the period. Morgan Stanley grew its position in shares of Allena Pharmaceuticals by 126.0% in the third quarter. Morgan Stanley now owns 1,856,640 shares of the company’s stock valued at $19,941,000 after purchasing an additional 1,034,990 shares during the period. Sphera Funds Management LTD. grew its position in shares of Allena Pharmaceuticals by 10.4% in the third quarter. Sphera Funds Management LTD. now owns 295,199 shares of the company’s stock valued at $3,170,000 after purchasing an additional 27,850 shares during the period. Finally, Partner Fund Management L.P. grew its position in shares of Allena Pharmaceuticals by 1.7% in the third quarter. Partner Fund Management L.P. now owns 1,768,568 shares of the company’s stock valued at $18,994,000 after purchasing an additional 28,763 shares during the period. 84.39% of the stock is owned by institutional investors.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Further Reading: What are Institutional Investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.